Ane-Kristine Finbråten

Dr. Ane-Kristine Finbråten


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2015 in Developmental Medicine & Child Neurology
Verified
Journal Article
Closed access
PDF file
AFAne-Kristine Finbråten
Ane-Kristine Finbråten
CMCatia Martins
Catia Martins
GAGuro Lillemoen Andersen
Guro Lillemoen Andersen
JSJon Skranes
Jon Skranes
BBBente Brannsether
Bente Brannsether
TVTorstein Vik
Torstein Vik

14 August 2014 in Osteoporosis International
Verified
Journal Article
Closed access
PDF file
AFAne-Kristine Finbråten
Ane-Kristine Finbråten
USU. Syversen
U. Syversen
JSJ. Skranes
J. Skranes
GAG. L. Andersen
G. L. Andersen
RSR. D. Stevenson
R. D. Stevenson
TVT. Vik
T. Vik

27 May 2024 in Viruses
Verified
Journal Article
Open access
PDF file
KMKristian Braathen Malme
Kristian Braathen Malme
KSKathrine Stene-Johansen
Kathrine Stene-Johansen
IKIngvild Klundby
Ingvild Klundby
ØBØystein Sager Backe
Øystein Sager Backe
TFTarjei Foshaug
Tarjei Foshaug
HMHåvard Midgard
Håvard Midgard
Treatment of hepatitis C among people who inject drugs (PWID) may be complicated by loss to follow-up and reinfection. We aimed to evaluate sustained virologic response (SVR) and reinfection, and to validate complete pharmacy dispensation as a proxy for cure among PWID enrolled in a trial of opportunistic HCV treatment. Data were obtained by reviewing the electronic patient files and supplemented by outreach HCV RNA testing. Reinfection was defined based on clinical, behavioral, and virological data. Intention to treat SVR ≥ 4 within 2 years after enrolment was accomplished by 59 of 98 (60% [95% CI 50–70]) during intervention conditions (opportunistic treatment) and by 57 of 102 (56% [95% CI 46–66]) during control conditions (outpatient treatment). The time to end of treatment response (ETR) or SVR ≥ 4 was shorter among intervention participants (HR 1.55 [1.08–2.22]; p = 0.016). Of participants with complete dispensation, 132 of 145 (91%) achieved ETR or SVR > 4 (OR 12.7 [95% CI 4.3–37.8]; p < 0.001). Four cases of reinfection were identified (incidence 3.8/100 PY [95% CI 1.0–9.7]). Although SVR was similar, the time to virologic cure was shorter among intervention participants. Complete dispensation is a valid correlate for cure among individuals at risk of loss to follow-up. Reinfection following successful treatment remains a concern.

28 October 2024 in European Journal of Public Health
Verified
Journal Article
Open access
PDF file
AFAne-Kristine Finbråten
Ane-Kristine Finbråten
This presentation delves into the inequities faced by individuals with substance use disorder (SUD), with a particular focus on people who use drugs (PWUD) and people who inject drugs (PWID). Individuals contending with SUD encounter multifaceted barriers that hinder access to appropriate care and support. This presentation will highlight the discourse surrounding biases that exacerbate health disparities among PWUD and PWID. Structural stigma and discriminatory practices not only impede access to healthcare services but also perpetuate social exclusion, amplifying the challenges faced in seeking help and support. PWUD and PWID often require tailored interventions that address not only their substance use but also co-occurring physical and mental health conditions. However, the fragmented nature of healthcare delivery and the lack of integration between substance use treatment and mainstream healthcare services pose significant obstacles to holistic care provision. Drawing on empirical evidence and lived experiences, this presentation explores strategies to dismantle the barriers faced by individuals with SUD in Norway. Ultimately, this presentation aims to foster dialogue that addresses the inequities entrenched in healthcare systems around the world. By advocating for a compassionate and inclusive approach to SUD care, we can strive towards a society where all individuals, regardless of their substance use history, can access the support and resources they need to lead healthy and fulfilling lives.

13 May 2014 in Tidsskrift for Den norske legeforening
Verified
Journal Article
Open access
AFAne-Kristine Finbråten
Ane-Kristine Finbråten

11 December 2012 in Tidsskrift for Den norske legeforening
Verified
Journal Article
Open access
AFAne-Kristine Finbråten
Ane-Kristine Finbråten
BIBarne- Og Kvinnesykdommer Ved Norges Teknisk-Naturvitenskapelige Universitet&Period; Ingen Oppgitte Interessekonflikter&Period
Barne- Og Kvinnesykdommer Ved Norges Teknisk-Naturvitenskapelige Universitet&Period; Ingen Oppgitte Interessekonflikter&Period